The efficacy and safety of mycophenolate mofetil (MMF) in combination with CsA and prednisolone for the treatment of acute and chronic GVHD (aGVHD and cGVHD, respectively) after BMT and PBSCT from HLA-mismatched and -matched donors was evaluated in an open single center trial. Twenty-four patients, 17-48 years of age, with acute (n = 17) and chronic GVHD (n = 7) were treated with 2 g MMF daily in addition to CsA and prednisolone. Overall grade improvement of aGVHD was found in 11 of 17 (65%) patients treated with MMF. MMF therapy in the treatment of cGVHD led to moderate improvement in three of six patients with limited cGVHD. The most common adverse hematologic events of MMF were leukopenia (n = 6), anemia (n = 4) and thrombocytopenia (n = 3). Hematological adverse events were not severe and did not require the discontinuation of MMF. In this preliminary study, we have shown that MMF can be used safely for the treatment of aGVHD. In addition, the MMF therapy resulted in significant dose reduction of prednisolone for the treatment of GVHD. Keywords: mycophenolate mofetil; GVHD; bone marrow transplantation Allogeneic BMT is an effective therapy for a variety of malignant hematopoietic disorders. One of the limitations of such therapy is donor availability. Less than 30% of patients will have an HLA-matched related donor and Ͻ5% will have a one HLA locus mismatched related donor.
1,2
HLA-matched unrelated donors (MUD) are an alternative for the patients lacking a suitable family member. [3] [4] [5] However, the risks of developing aGVHD and cGVHD after MUD as well as after HLA-mismatched related transplants are significantly higher than after a BMT from an HLAmatched sibling. [6] [7] [8] The combination of immunosuppressive drugs, CsA, prednisolone and short-course MTX is an effective regimen for prevention of GVHD after BMT. 8, 9 However, the incidence reported for aGVHD grades II-IV after transplanCorrespondence: Dr A Fauser, Clinic of Bone Marrow Transplantation and Hematology/Oncology, Dr Otmar Kohler Str. 2, 55743 Idar Oberstein, Germany Received 11 August 1997; accepted 14 February 1998 tation from HLA-matched MUD is 78% and the incidence for grades III and IV is 36%. The incidence of cGVHD is 64%. 10 Since GVHD contributes to morbidity and mortality after MUD BMT, more effective prophylaxis and therapy for this severe complication are needed. 11, 12 MMF is a potent, uncompetitive, reversible inhibitor of eukaryotic inosine monophosphate dehydrogenase. It is an immunosuppressant that selectively inhibits proliferation of T and B lymphocytes and is successfully used for the prevention of acute rejection in primary cadaveric renal allograft recipients. 13 However, very little is known about the effect of MMF in prevention or treatment of GVHD in experimental animals.
14 In addition, no data on the use of MMF in the treatment of GVHD after BMT are available. The aim of our study was to evaluate the safety and efficacy of MMF in the treatment of aGVHD and cGVHD in patients after allogeneic BMT.
Patients and methods
This study included 24 patients given sibling BM (n = 6; four of which were HLA mismatched) or PBSCT (n = 3; two of which were mismatched) or allogeneic MUD BM (n = 14; two of which were HLA mismatched) or PBSCT (n = 1) (Table 1) , from December 1995 to February 1997. Of these patients, 15 had AML, six had CML and three had ALL. Three patients received a second BMT as therapy for relapsing leukemia after the first MUD BMT (n = 2) or first autologous BMT (n = 1). The male to female ratio was 17:7 and the median age was 37 (range 17-48).
Conditioning regimens included TBI and CY in 19 of 24 patients. A BU/VP16 regimen was used in three patients all of whom were receiving a second BMT, in order to be potentially noncross-resistant to that used for the initial transplant (TBI/CY). The BU/CY regimen was used in two patients. The TBI/CY regimen consisted of TBI with a total dose of 13.5 Gy on days −7, −6 and −5, and then CY 60 mg/kg once daily i.v. on 2 successive days.
Engraftment was defined as the first of two successive days after marrow transplantation with a neutrophil count Ͼ0.5 × 10 9 /l.
GVHD prophylaxis
Acute GVHD prophylaxis for HLA-mismatched related BMT as well as for MUD-mismatched or identical BMT consisted of a combination of CsA (5 mg/kg) daily starting on day −3 and MTX on day +1 (15 mg/m 2 ) and days +3 and +6 (10 mg/m 2 ). From day +7 the patient received prednisolone at a dose of 0.5 mg/kg daily and from day +14 1 mg/kg. The full dose of CsA was administered i.v. until day +3 when the dose was adjusted according to the median serum level determined twice weekly. As soon as the patient recovered from conditioning regimen-induced gastrointestinal toxicity CsA was given orally. After day 60 the CsA was decreased by 5% per week 15 up to day 180. Prednisolone was also tapered over the first year. Five patients in the study group and five patients in the control group received HLA-identical BMT or PBSCT and received only CsA and prednisolone for GVHD prophylaxis.
GVHD treatment
Patients with aGVHD (71%) were treated with a combination of MMF, prednisolone and CsA. They received 250 mg MMF four times daily orally (total daily dose 1 g). In a week, the dose was increased to a total daily dose of 2 g. The full dose of MMF was administered continuously unless adverse effects developed. Prednisolone was used at a dose of 1 mg/kg, and CsA according to the serum level (200-300 mol/ml). The plan was to treat patients for 14 days at the full dose and then begin to taper.
Patients with cGVHD (29%) were treated with continued immunosuppression. Similarly to patients with aGVHD, patients with clinical limited and extensive cGVHD received 250 mg MMF four times daily orally (total daily dose 1 g). In a week, the dose was increased to a total daily dose of 2 g. The full dose of MMF was administered continuously unless adverse effects developed. Prednisolone was used at a dose of 0.3 mg/kg.
Inclusion criteria
Acute GVHD was graded and staged according to the Consensus Conference on aGVHD grading. 16 This staging systems is highly reproducible when tested in an international survey and is recommended for reports of GVHD prevention and treatment in order to improve comparability between series. Treatment with MMF in addition to CsA was initiated on days +15 to +75 for the treatment of acute GVHD manifesting as the involvement of skin, liver or gastrointestinal tract ( Table 2) . Twelve of 17 patients had stages 2-3 skin GVHD, eight of 17 had stages 1-4 liver GVHD and four of 17 had gut GVHD. Seven of 17 patients had both skin and liver GVHD. In patients with chronic GVHD, the treatment with MMF was initiated on days +131 to +705 after BMT.
Chronic GVHD was graded and staged according to the clinicopathological classification of GVHD, 17 which is also highly reproducible when tested in an international survey and is recommended for reports of GVHD prevention and treatment in order to improve comparability between series. In patients with chronic GVHD, treatment with MMF was initiated on days +131 to +705 after BMT. Six patients had limited cGVHD and one patient had extensive cGVHD.
Adverse events
At each study visit, patients were evaluated for adverse hematological events, opportunistic infections and gastrointestinal disturbances. 
Statistical analysis
The Kaplan-Meier method was used to estimate the probability of relapse rate and overall survival. 18 The difference between groups was compared using the Student's t-test.
Results
A total of 24 patients were treated with MMF between December 1995 and February 1997 ( Table 1 ). All patients successfully engrafted and developed aGVHD and/or cGVHD. The efficacy of MMF on aGVHD and cGVHD after BMT is summarised in Table 2 . The average time on MMF therapy for our patients was 120 days (range 14-200 days). Fourteen of 15 patients with stages 1-4 skin aGVHD showed improvement of the skin. An improvement in liver aGVHD was noted in four of eight patients treated with MMF. Two of four patients with gut aGVHD improved after treatment with MMF. Overall grade improvement of aGVHD was found in 11 of 17 patients (65%). A positive effect of MMF in the treatment of cGVHD was found in three of six patients with limited cGVHD. One patient with extensive cGVHD worsened with MMF therapy.
The most common adverse hematologic events of MMF are leukopenia and anemia. Leukopenia was noted in six of 24 patients, anemia in four of 24 patients. Thrombocytopenia was found in three of 24 patients. However, it should be noted that adverse hematological events were not severe and did not require discontinuation of MMF. In two patients with leukopenia and anemia, the dose of MMF was reduced from 2 g to 1.5 g. CMV infection was observed in four of 24 patients, Herpes simplex-associated stomatitis in one of 24 patients, Candida albicans/Candida crusei stomatitis in five of 24 patients and Aspergillosis (lung) in one patient. Herpes zoster was detected in one patient while Pneumocystis carini was not found in any patient receiving MMF.
Adverse gastrointestinal events including diarrhea, nausea and vomiting were observed in four of 24 patients receiving MMF. No nephrotoxicity or liver toxicity was noted in our patients except for one patient, who was treated with MMF for 120 days because of extensive cGVHD and who developed progressive liver toxicity. However, progressive liver toxicity in this particular patient was probably primarily the result of uncontrollable progressive multiorgan failure rather than an effect of MMF.
It should also be noted that severe adverse effects of prednisolone therapy, ie steroid-induced diabetes, osteoporosis with bone fractures and psychotic behaviour requiring hospitalization and antipsychotic treatment, were not found in patients treated with MMF.
Among MMF-treated patients four out of 24 relapsed (Figure 1) . The Kaplan-Meier estimate of overall survival was 81% at 12 months. All of the relapsed patients had aGVHD in the post-transplant period. Two patients had Ph + c-ALL and relapsed at days +76 and +187. One patient had blast crisis of CML and relapsed at day +176 and one patient had AML and relapsed at day +141. All four relapsed patients were transplanted with active disease.
The median follow-up is 45 weeks; the Kaplan-Meier estimate of overall 1 year survival rate is 47% (Figure 1 ). Thirteen patients out of 24 died, 10 with aGVHD and three with cGVHD. Two of them died from bleeding (one GI tract and one urinary), six from severe pneumonia, two with infectious complications, two with liver failure and one patient with Aspergillosis of the lung.
Discussion
The most frequently used immunosuppressive prophylaxis after allogeneic marrow transplantation includes the combination regimen of CsA, prednisolone and short-course MTX. 8, 9 However, the proportion of patients developing aGVHD and cGVHD and the subsequent morbidity and mortality are still very high. 7, 8, 10 This is the reason for encouraging further investigations and clinical trials of new immunosuppressive agents which may be of use in the treatment of GVHD. A recent phase II study carried out to Time (days) Figure 1 Kaplan-Meier estimation of the probability of the relapse rate (-) and overall survival (-) of 24 patients after allogeneic BMT or PBSCT who received MMF in combination with prednisolone for GVHD treatment. The probability of relapse and overall survival at 12 months is 81 and 47%, respectively.
evaluate the combination of the macrolide FK506 and short-course MTX showed activity of this combination in preventing aGVHD after MUD transplants. However, nephrotoxicity occurred in 74% patients. 11 Our pilot study is the first to evaluate the use of MMF in combination with CsA and prednisolone in the treatment of GVHD.
Our results show that MMF can be safely used for the treatment of aGVHD. Although our study group of patients had very diverse clinical features making it difficult to reach a conclusion on the efficacy of MMF, we emphasize that most patients treated with MMF experienced significantly improved clinical symptoms of aGVHD. In addition to this, none of them required additional therapy. It is of note that three out of 17 patients received a second transplant, with a higher incidence of regimen-related toxicity. However none of them showed significant toxicity and responded well to MMF. Furthermore, it should be noted that treatment with MMF was not discontinued in any of our patients because of adverse events. Improvement in cGVHD after MMF therapy was moderate thus indicating that MMF should be used earlier in the post-transplant period with the aim of improving aGVHD and preventing the development of cGVHD.
The frequency of adverse events observed in our study did not require the discontinuation of MMF. However, adverse hematological events required dose reduction in two patients. The frequency of adverse events in our study was similar to the data already reported 13, 19 with the same dose of 2 g daily. It has already been reported that the frequency of adverse events appears to be dose related.
The advantages of MMF when compared to other new immunosuppressive drugs may be a relatively low incidence of adverse events. No nephrotoxicity or liver toxicity was noted in our patients except for one patient who had extensive cGVHD and developed progressive liver toxicity while on MMF therapy. However, the progressive liver toxicity in this particular patient was likely to have been a result of progressive multiorgan failure rather than the effect of MMF.
A rationale for effective use of immunosuppressive drugs in a combination regimen is provided by their different mechanisms of action. However, the adverse effects of prednisolone and CsA make the control of GVHD difficult. One third of the patients treated with prednisolone for aGVHD developed severe adverse effects to prednisolone therapy making GVHD treatment difficult. Comparing our data to an historical control group of patients (matched for underlying disease, age, gender, transplant and transplant regimen) we demonstrated a significant reduction in prednisolone requirement, as shown in Figure 2 (P Ͻ 0.01). In this preliminary study, we have shown that administration of MMF allows a significant dose reduction of prednisolone during MMF therapy when compared to the patients with GVHD who were treated with high-dose prednisolone therapy in combination with CsA (not included in this study), indicating the clinically important steroid sparing effect of MMF.
In conclusion, in order to substantiate our preliminary data, a prospective, randomised clinical trial is needed to assess the impact of MMF in the treatment of aGVHD and cGVHD. (----) . Each point represents a percent of prednisolone therapy compared to 100% (100% represents mean of 55 ± 15 mg for patients with aGVHD and 15 ± 5 mg for patients with cGVHD). **P Ͻ 0.01 (Student's t-test).
